Aventis Savian
Executive Summary
Propentofylline development for Alzheimer's is halted after the Phase IIIb Propentofylline Long-term Use Study demonstrated no difference versus placebo. Aventis was finalizing the protocol for an additional Phase III study in the U.S., slated to begin in early 2000. Aventis' attempt to gain approval in Europe for the glial cell modulator was met with a negative opinion by the Committee for Proprietary Medicinal Products in 1998, which was upheld in 1999 after the company appealed the decision (1"The Pink Sheet" July 26, 1999, p. 18)